| Author | dc.contributor.author | Galarce, Gloria D. | |
| Author | dc.contributor.author | Foncea, Rocío | es_CL |
| Author | dc.contributor.author | Edwards, Ana María | es_CL |
| Author | dc.contributor.author | Pessoa Mahana, Hernán | es_CL |
| Author | dc.contributor.author | Pessoa Mahana, Carlos David | es_CL |
| Author | dc.contributor.author | Ebensperger González, Roberto | es_CL |
| Admission date | dc.date.accessioned | 2010-01-22T13:32:34Z | |
| Available date | dc.date.available | 2010-01-22T13:32:34Z | |
| Publication date | dc.date.issued | 2008 | |
| Cita de ítem | dc.identifier.citation | BIOLOGICAL RESEARCH Volume: 41 Issue: 1 Pages: 43-50 Published: 2008 | en_US |
| Identifier | dc.identifier.issn | 0716-9760 | |
| Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/120861 | |
| Abstract | dc.description.abstract | This study describes the effect of novel 6-Arylbenzimidazo[1,2-c]quinazoline derivatives as tumor necrosis factor alpha (TNF-alpha) production inhibitors. The newly synthesized compounds were tested for their in vitro ability to inhibit the lipolysaccharide (LPS) induced TNF-alpha secretion in the human promyelocytic cell line HL-60. The compound 6-Phenyl-benzimidazo[1,2-c]quinazoline, coded as G1, resulted as the most potent inhibitor and with no significant cytotoxic activity. Thus, 6-Arylbenzimidazo[1,2-c]quinazoline derivatives may have a potential as anti-inflammatory agents. | en_US |
| Lenguage | dc.language.iso | en | en_US |
| Publisher | dc.publisher | SOC BIOLGIA CHILE | en_US |
| Keywords | dc.subject | ANTITUMOR | en_US |
| Título | dc.title | Biological evaluation of novel 6-arylbenzimidazo [1,2-c]quinazoline derivatives as inhibitors of LPS-induced TNF-alpha secretion | en_US |
| Document type | dc.type | Artículo de revista | |
